CClinicalTrials.gg
RecruitingNCT05060952Updated Sep 29, 2021

Calprotectin in Chronic Prosthetic Joint Infection

An observational study in Prosthetic Joint Infection, Prosthetic Infection and Arthroplasty Complications, sponsored by Technical University of Munich. Recruiting at 1 site in Germany. Per ClinicalTrials.gov, last updated 2021-09-29.

Sponsored by Technical University of Munich · Observational

From the registry’s dates

  • Primary completion was expected by Dec 2023, 2 years 9 months ago, but the record still lists the study as recruiting.
  • Started Mar 2019; still recruiting 7 years 7 months later.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
500
Sex
All
01

Study summary

A bacterial infection of an artificial joint is a serious complication that often requires additional surgery to exchange the arthroplasty. It is also difficult to recognize an infected joint, as the symptoms caused by the infection are very similar to those of other problems with arthroplasties, such as loosening of the implant. To improve the ability to diagnose prosthetic joint infections, this study compares the levels of calprotectin, a specific inflammatory protein, in the joint fluid of infected joints and joints with other complications. The underlying hypothesis is that the level of calprotectin in infected joints is significantly higher, thus facilitating the diagnosis of prosthetic joint infection.

02

Conditions studied

  • Prosthetic Joint Infection
  • Prosthetic Infection
  • Arthroplasty Complications
03

In context

Infections

6,687 studies on the registry are indexed under Infections; 807 are open to participants now.

This study's planned enrollment of 500 is above the median of 240 across 2,136 observational studies indexed under Infections.

Browse Infections studies →

Lead sponsor

Technical University of Munich is the lead sponsor of 315 studies on the registry; 55 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with painful or failed arthroplasty of the hip or knee joint scheduled for partial or complete arthroplasty exchange.

Inclusion criteria

  • scheduled arthroplasty exchange for any of the following reasons:
  • infection
  • loosening
  • instability
  • malalignment
  • periprosthetic fracture

Exclusion criteria

Exclusion Criteria:

  • acute prosthetic joint infection
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
500 participants (estimated)
Patient registry
No

Groups and cohorts

  • PJI

    Patients with septic arthroplasty failure

    Diagnostic Test: Calprotectin Lateral Flow Test

  • Aseptic

    Patients with aseptic causes of arthroplasty failure

    Diagnostic Test: Calprotectin Lateral Flow Test

Interventions

  • Diagnostic testCalprotectin Lateral Flow Test

    Semiquantitative point of care photometric assay for the calprotectin level in joint fluid aspirate

06

What researchers measure

Primary outcomes

  1. Diagnostic accuracy of synovial fluid calprotectin

    The level of synovial fluid calprotectin measured in joint fluid aspirate as a diagnostic test for prosthetic joint infection. The accuracy is calculated by comparing its results with the International Consensus Meeting (ICM) on prosthetic joint infection criteria of 2018.

    Time frame: Intraoperatively

07

Study locations

1 of 1 sites recruiting
  • Department of Orthopedics and Sports Orthopedics, Klinikum rechts der Isar, Technical University Munich
    Munich, Bavaria 81675, Germany
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 29, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05060952
Lead sponsor
Technical University of Munich
Responsible party
Christian Suren (Associate Professor, Technical University of Munich) — Principal investigator
First posted
Sep 29, 2021
Start date
Mar 1, 2019
Primary completion
Dec 31, 2023 (estimated)
Completion
Dec 31, 2025 (estimated)
Last update
Sep 29, 2021

Study contacts

Christian Suren, M.D.
Contact
christian.suren@tum.de
+49 89 4140 ext. 2271

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion